Beyond Air, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
XAIR Nasdaq 3840 www.beyondair.net

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Beyond Air, Inc.

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 - Apr 20th, 2026 6:00 am
Beyond Air to Participate in the D. Boral Capital Global Conference 2026 - Apr 15th, 2026 6:00 am
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) - Apr 1st, 2026 7:00 am
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO - Mar 26th, 2026 2:05 pm
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial - Mar 17th, 2026 2:35 pm
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am
Beyond Air to Participate in the 38th Annual Roth Conference in March - Mar 11th, 2026 5:00 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - Mar 10th, 2026 8:21 am
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - Mar 10th, 2026 5:30 am
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies - Mar 4th, 2026 3:39 am
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval - Feb 25th, 2026 2:07 pm
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... - Feb 20th, 2026 6:00 pm
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - Feb 20th, 2026 6:00 am
Beyond Air, Inc. Q3 2026 Earnings Call Summary - Feb 13th, 2026 2:32 pm
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - Feb 13th, 2026 5:30 am
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 - Feb 4th, 2026 6:00 am
XTL Update on Recent Developments - Jan 29th, 2026 2:05 pm
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences - Jan 27th, 2026 2:05 pm
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast - Jan 26th, 2026 2:05 pm
Top Midday Decliners - Jan 14th, 2026 12:10 pm